Fujing Zhang

Peking Union Medical College Hospital
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.

Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.

Journal: Cancer medicine

Published: October 17, 2025

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab.

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab.

Journal: Journal of translational medicine

Published: November 20, 2024

Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.

Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.

Journal: Frontiers in immunology

Published: June 13, 2024

Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.

Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.

Journal: Molecular imaging and biology

Published: May 17, 2024

Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.

Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.

Journal: Clinical nuclear medicine

Published: April 17, 2024

Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study.

Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study.

Journal: Journal of bone oncology

Published: February 28, 2024

Impaired acute-phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS-CoV-2 Omicron variants outbreak infection.

Impaired acute-phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS-CoV-2 Omicron variants outbreak infection.

Journal: International journal of cancer

Published: December 16, 2023

Myc rearrangement redefines the stratification of high-risk multiple myeloma.

Myc rearrangement redefines the stratification of high-risk multiple myeloma.

Journal: Cancer medicine

Published: August 09, 2023

Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone.

Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone.

Journal: Chronic diseases and translational medicine

Published: July 22, 2023

Pathophysiology and therapeutic advances in myeloma bone disease.

Pathophysiology and therapeutic advances in myeloma bone disease.

Journal: Chronic diseases and translational medicine

Published: April 19, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026